No money was injured while filming

At about mid-day, the Dow is off nearly -4%, the Nasdaq is off nearly -4.5%, and the S&P 500 is down just over -4%. It’s not a good day, and things are really looking nasty for several stocks. Here’s a look at some of today’s biggest losers so far.

NetApp Inc. (NASDAQ: NTAP) is down about -19% and has posted a new 52-week intra-day low of $33.32 following a poor earnings report, a weak forecast, and a downgrade from FBN. The stock is setting the pace for tech weakness after it pointed out that NetApp is expecting a “dramatic slowdown” in sales.

JDS Uniphase Corp. (NASDAQ: JDSU) is off -10.5%, at $10.47, within a 52-week range of $9.09-$29.12. The company managed to dodge a downgrade, but yesterday’s earnings and guidance combined with NetApp’s warning have clobbered the stock.

Invesco Mortgage Capital Inc. (NYSE: IVR) is off more than -8.5%, at $17.63, in a 52-week range of $16.48-$24.07. The company has announced a secondary offering of 20 million shares at $18.37/share, $0.92/share lower than yesterday’s closing price. Shareholders hate that sort of thing.

Citigroup Inc. (NYSE: C) shares are off around -7%, at $27.90, in a 52-week range of $26.25-$51.50. There’s no specific news that would lead to this drop, just the usual worries on European debt, home sales, and any of a number of economic concerns.

Camelot Information Systems Inc. (NYSE: CIS) is down more than -31%, at $5.87, having already posted a new 52-week low this morning of $4.90. That’s down nearly -80% from its 52-week high of $28.18. The company missed both profit and revenue estimates. There have also been some questions recently about the company’s truthfulness in reporting.

Gentium SpA (NASDAQ: GENT) is off more than -30%, at $6.12, within a 52-week range of $4.53-$13.69. The Italian drug maker has withdrawn a marketing application for an experimental treatment for complications resulting from stem cell transplants.

Acme Packet, Inc. (NASDAQ: APKT) is down nearly -18%, at $41.25, in a 52-week range of $30.70-$84.50. The communications equipment maker’s stock was downgraded by Pacific Crest, and is wallowing in the NetApp disaster.

Riverbed Technology Inc. (NASDAQ: RVBD) is down nearly -16%, at $20.53, in a 52-week range of $17.36-$44.70. Another communications equipment vendor and another downgrade at Pacific Crest.

The Direxion Daily Technology Bull 3X Shares (NYSE: TYH) is down nearly -16%, at $29.00, in a 52-week range of $23.66-$57.23. The triple-leveraged ETF is getting pulverized on its long technology bet.

MGM Resorts International (NYSE: MGM) is off -12%, at $10.15, in a 52-week range of $8.92-$16.94. Investor Kirk Kerkorian’s Tracinda Corp. reported yesterday that he has shed 20 million MGM shares. Tracinda is still the largest shareholder in MGM with nearly a stake of nearly 27% .

EMC Corp. (NYSE: EMC) is off more than -10%, at $20.22, in a 52-week range of $17.90-$28.73. The company is down about -24% in the past month, and today is following the downward spiral created by NetApp.

Bank of America Corp. (NYSE: BAC) is among the volume leaders with the largest share price downturns today. Shares are down nearly -7%, at $6.96, in a 52-week range of $6.31-$15.31. Worries about bank stocks are growing as reports on the global economy get gloomier.

Oracle Corp. (NASDAQ: ORCL) has already traded more shares than its daily average of more than 34 million. Shares are off nearly -8%, at $25.35, within a 52-week range of $21.66-$36.50. No particular news except the general disillusionment with tech stocks following NetApp’s pronouncement.

Paul Ausick

Caribou Coffee Company, Inc. (NASDAQ: CBOU) is giving up even more on an insider secondary offering with the shares down 7.8% at $13.60.

Gentium S.p.A (NASDAQ: GENT) is a loser that is less of a loser than originally indicated. The company withdrew its NDA for Defibrotide after FDA cited numerous “Refuse to File” issues. The FDA has also requested that Gentium conduct additional quality reviews and requested additional details regarding the conduct and monitoring of the trials by the independent review committee.  Ouch.  Shares closed down 2% at $8.79 on Wednesday and shares were down close to 30% at $6.30 in the after-hours session after it was reopened.  The reaction this morning is down “only” 19.9% at $7.04.

Invesco Mortgage Capital Inc. (NYSE: IVR) is down on another secondary offering.  The mortgage REIT had one secondary offering at the end of June and it has now said that it will sell 20 million more in shares.  Shares are trading down over 6% at $18.06 in pre-market trading.

JA Solar Holdings Co., Ltd. (NASDAQ: JASO) is down after posting a loss and lowering its sales guidance for the next quarter.  Shares are down more than 11% at $3.40 this morning.

JDS Uniphase Corporation (NASDAQ: JDSU) is almost considered impressive when you consider the snap-back reaction…. The fiber optic leader reported $0.04 net EPS on $0.23 adjusted EPS.  The guidance is where the trouble comes into play.  Shares closed down 1.7% at $11.70 and the stock initially was down more than 10% last night.  This morning we have shares down a mere 3% at $11.35.  A loss that is a win.

NetApp, Inc. (NASDAQ: NTAP) is hitting new 52-week lows by the looks of it.  The company reported $0.54 EPS guided earnings down at $0.38 to $0.42 EPS for next quarter.  The company also announced the retirement of its CFO.  Shares were down over 3% at $41.66 on Wednesday but the stock is now down over 13% at $35.93 on Thursday morning.  Keep in mind that the prior 52-week low was $38.00.

Sina Corp. (NASDAQ: SINA) is one of the few winners even after the net profit fell on rising costs.  Sales were up 20% and it is growing the user base.  The ADR is up 3% at $95.75.

European banks are getting hammered all over again.  Here are some of the ADRs getting hit:

• Barclays PLC (NYSE: BCS) is down 7.3% at $10.73;
• Lloyds Banking Group plc (NYSE: LYG) is down 6.9% at $2.00;
• Credit Suisse Group (NYSE: CS) is down 4.8% at $27.91.
• Alcatel-Lucent (NYSE: ALU) is no bank but shares are down 4.6% at $3.53 as a leveraged tech proxy from Europe.

JON C. OGG

Hot Topic Inc. (NASDAQ: HOTT) is higher as a turnaround stock, but it lost $6.2 million for the quarter to come in at -$0.14 EPS.  The boost is from a $25 million share buyback plan.  Shares fell 1% in regular trading to $6.95, but the stock is up 4% at $7.23 in the after-hours.

Invesco Mortgage Capital Inc. (NYSE: IVR) had already had one secondary offering not too long ago at the end of June, and now it has signaled that it will sell 20 million more in shares.  Shares are trading down 3.3% at $18.65 in the after-hours session.

JDS Uniphase Corporation (NASDAQ: JDSU) is down considerably after turning in a mere $0.04 net EPS on $0.23 adjusted EPS.  The guidance is where the trouble comes into play.  Shares closed down 1.7% at $11.70 and the stock is now down what is approaching double-digits in percentage terms at $10.60.

Limited Brands, Inc. (NYSE: LTD) is bucking some of the margin issues in retail apparel stores.  The company posted $0.48 EPS vs. $0.46 estimates and it raised 2011 guidance to $2.35 to $2.40 EPS after giving same-store sales guidance for the next quarter in the high single-digit range.  Shares were down 1.4% at $34.34 today but the stock is now up 3.6% at $35.50 in the after-hours.

NetApp, Inc. (NASDAQ: NTAP) is hurting: The company reported earnings of $0.54 EPS before items and gave guidance for earnings down at $0.38 to $0.42 EPS for next quarter.  The company also announced the retirement of its CFO.  Shares were down over 3% at $41.66 today, but now the stock is down more than 11% more at $36.95 in the after-hours session.  What will hurt more than anything is that the prior 52-week low was $38.00.  So much for this one being immune to the market and economy.

PetSmart, Inc. (NASDAQ: PETM) looked ok on the surface at $0.54 EPS vs. $0.51 estimates.  The company also put 2011 guidance at $2.40 to $2.48 EPS versus a prior target of $2.32 to $2.42 EPS. The problem is that Thomson Reuters was already at $2.43 EPS.  Shares closed down $0.03 at $41.56 and the after-hours market is down more than 3% at $40.15 in the after-hours.

Synopsys Inc. (NASDAQ: SNPS) said revenue rose almost 15% to $386.8 million and gave guidance for next quarter for revenues to be in a range of $386 to $392 million.  It also gave guidance of $1.531 to $1.537 billion in 2011 sales, all of which are slightly above estimates from Thomson Reuters.  Shares closed up 3.8% at $23.44 and the stock is up another 1.5% at $23.80 in the after-hours session.

Gentium S.p.A (NASDAQ: GENT) is getting whacked after announcing that the company was withdrawing its NDA for Defibrotide after recent correspondence from the FDA identifying numerous “Refuse to File” issues regarding the completeness of the datasets for both the treatment and prevention studies. The FDA has also requested that Gentium conduct additional quality reviews and requested additional details regarding the conduct and monitoring of the trials by the independent review committee.  Ouch.  Shares closed down 2% at $8.79 but the stock is down close to 30% at $6.30 in the after-hours session.

Some of these prices may be grossly different after the conference calls and by the morning.

JON C. OGG

Included today is the news, the share move, relative performance and valuation data, and added in additional market color where applicable.

UPDATED FOR CLOSING BELL PRICES

Cell Therapeutics, Inc. (NASDAQ: CTIC) is continuing to see traders buy up the stock after Monday’s FDA denial implosion.  Frankly, the moves higher here are becoming harder and harder to explain other than “trader sentiment” and the pesky minutes charts used by traders.  This still seems to be more like “sell therapeutics” based on the news, but the move has actually been one of recovering losses.   Shares have come well off the highs today but the stock is still up 8.7% at $0.697 on 53 million shares. UPDATE FOR CLOSE: shares closed up only 1.6% at $0.647 on 72 million shares.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported last night that its Q4 net loss was $4.3 million or -$0.18 per share versus a net loss of $7.9 million or -$0.39 per share for Q4-2008.  Shares are down 4.4% at $2.40 on only about 1.3 million shares.  This one is too small for an earnings analysis. UPDATE FOR CLOSE: shares closed down 5.2% at $2.38 on 1.844 million shares.

China Biologic Products, Inc. (NASDAQ: CBPO), a Chinese player you may have never known, is one of the larger gainers in the sector today.   The plasma-based biopharma reported last night that Q4 revenues increased 185.6% year-over-year to $37.6 million, and excluding Dalin, revenues rose 46.7% year-over-year to $19.3 million or 51.4% of total revenue.  The company also showed that gross profit increased 208.6% year-over-year to $27.3 million.   This is up 15% at $10.44 on almost 400,000 shares.  The 52-week range is $1.69 to $13.70 and the average volume is only 135,000 shares for this $244 million market cap Chinese player. UPDATE FOR CLOSE: shares closed up 24% at $11.26 on 504,000 shares.

Gentium S.p.A (NASDAQ: GENT) is one of the biggest winners today of all sectors, not just biotech and biohealth.   In a presentation data, its Defibrotide was shown to generate a 40% drop in the incidence of hepatic veno-occlusive disease in what was called high-risk pediatric patients within 30 days after stem cell transplant.  Stem cells.   Shares are up a whopping 56% at $2.82 on 2.8 million shares.  Average volume is only about 50,000 shares and the 52-week range is $0.36 to $4.00 for the tiny $42 million market cap.  UPDATE FOR CLOSE: shares closed up a whopping 77.5% at $3.23 on over 3.6 million shares.

Genzyme Corporation (NASDAQ: GENZ) effectively got the worst situation it could have for the troubled Allston plant.  This FDA enforcement action may need a third-party inspection and review of plant operations for an extended period and will require payments to the government.  The company believes that shipments out of the plant will continue on an uninterrupted basis, although it does not know the financial impact of the call yet.  Shares are down more than 6% or down by $3.80 at $55.30 on 11.5 million shares.  Unfortunately, its chart before today was starting to show something traders and investors might have thought was not this bad.  UPDATE FOR CLOSE: shares closed down 6.4% at $55.33 on 14.5 million shares.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) is soaring on an analyst upgrade after the firm was raised to Market Outperform from Market Perform at Rodman & Renshaw.  The price target is $10.00.  That still implied as double, because this stock is up 9.25% at $5.54.  The 231,000 shares compares to average volume of 35,000 shares and the 52-week range is $4.48 to $8.50.  UPDATE FOR CLOSE: shares closed up 10% at $5.58 on 275,000 shares.

Novavax, Inc. (NASDAQ: NVAX) loves swine flu, or so its stock says.  The stock is surging on positive results from a Phase I of its two-phase clinical study in Mexico for a H1N1 vaccine.  Shares are up 11.5% at $2.61 on almost 6 million shares.  Average volume is now back down to about 1.4 million shares per day.  UPDATE FOR CLOSE: shares closed up 10.7% at $2.59 on over 6.7 million shares.

Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) is down today after the company suspended its effort seeking regulatory approval for picoplatin in small cell lung cancer.  The company announced that it has also hired the firm Leerink Swann to conduct a review of strategic alternatives, but many seem to doubt its value or worth after disappointments.  This one is down 17.5% at $1.29 on almost 9 million shares.  Shares hit $1.18 today, a 52-week low.  UPDATE FOR CLOSE: shares closed down 16.8% at $1.30 on 10.19 million shares.

Amgen Inc. (NASDAQ: AMGN) and Warner Chilcott plc (NASDAQ: WCRX) have no news, but they are items you should consider today.  An unrelated dividend story showing Starbucks initiated its first dividend ever has investors looking for which others might be next in line. At BioHealthInvestor.com, we have previously outlined why these may become next in line for dividends.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

We have outlined the relative news, price moves, historic data, and relative color where applicable on each.

AP Pharma Inc. (NASDAQ: APPA) is getting crushed today after the FDA complete response letter failed to back its anti-nausea chemotherapy drug.  This one had risen yesterday ahead of the decision.  Shares are down 47% at $1.09 on about 30-times volume of more than 15 million shares.  The 52-week range is $0.38 – $2.16 and the market cap is just under $43 million now.

Genzyme Corp. (NASDAQ: GENZ) may be news from the outside or it may just be technical trading oriented.  There has been an article on noted CEO pressure and then there is the chart.  At $59.31 with a 3.3% gain, this is a multi-month high and toward the top of the $47.09 t $63.47 range over the last 52-weeks.

Gentium S.p.A (NASDAQ:: GENT) is a mystery mover and the only thing thrown out there is ‘takeover’ from chat rooms, yet there is nothing credible to back that up.  Literally, that was all there is and we’d tell you that if you have to rely solely on chats then life is changing again.  Shares are up 45% at $2.37 on over 550,000 shares.  The 52-week range is $0.36 to $2.37.

Merck & Co. Inc. (NYSE: MRK) is under a little pressure, but only about 1% at $38.00.  The FDA has issued a warning that its Zocor and Vytorin at the highest dosages could pose a greater muscle risk.

OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is out touting news to keep the heat on Astellas or other bidders to do better than the current $52.00 cash tender on the table.  It said its Roche partner on Tarceva has a favorable opinion from European drug regulators and expects a decision in 45 days for the drug.  Shares are up 0.6% at $59.06 today but put in an intra-day high of $59.50.

OXiGENE Inc. (NASDAQ: OXGN) is down 5% today and already seen triple its normal volume after the company has a ‘going concern’ opinion on its audited financial statements for 2009.  AT $1.14, its 52-week range is $0.62 to $2.78.

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) is trading up 1.3% at $9.33 and hit a new multi-year high of $10.60 earlier today.  This is as the traders are trying to maintain yesterday’s monster gains after its Silenor insomnia drug received an FDA backing.  This still only has a market cap of $221 million a the current price and we compared this to other big sleep-aid drugs in the battle against insomnia.

Theravance Inc. (NASDAQ: THRX) is now up 3% at $12.37 after the company sold 7.5 million shares at $11.50.  The stock was up at $12.50 earlier this week before the filing was made.  The lowest this stock hit today was $11.75, so frankly this looks like one of the better offerings out there from the therapeutics company.

On the mystery moves, or at least on moves with no real news on the tape… Celldex Therapeutics, Inc. (NASDAQ: CLDX) is up over 8% at $5.65 on 1.1 million shares versus a 52-week trading range of $4.16 to $14.19 and versus average volume of 360,000 shares.

JON C. OGG

BB&T Corp. (NYSE: BBT) was down about 1% after its secondary offering after S&P weighting changes.

Alcoa, Inc. (NYSE: AA) is down about 4% after an analyst downgrade from Goldman Sachs.

Century Aluminum Company (NASDAQ: CENX) is getting clipped by more than 6% this morning after yesterday’s gains.

Gentium S.p.A (NASDAQ: GENT) is surging on mixed Phase III treatment trial of Defibrotide for severe veno-occlusive disease.

EnerSys (NYSE: ENS) is indicated much lower on an insider-backer share sale of 3.2 million shares to Goldman Sachs.

Hewlett-Packard (NYSE: HPQ) is down after earnings, and we made some support calculations for key levels to watch in the coming days if the weakness persists here.

Cerus Corporation (NASDAQ: CERS) is seeing a huge surge on news that Swissmedic has approved the use of platelet components treated with Cerus’ INTERCEPT Blood System.

This volume took place late yesterday, but we started seeing elevated put and call options trading in Apple Inc. (NASDAQ: AAPL).  This could have been H-P related or it could have merely been options rolling trades from August to September ahead of Friday’s expiration.  So far AAPL shares are down less than 1% at $162.75 on only 100,000 shares.

-The 24/7 Wall Street Team